Mark Purcell
Stock Analyst at Morgan Stanley
(1.70)
# 3,023
Out of 4,708 analysts
5
Total ratings
50%
Success rate
1.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $96.83 | +17.73% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $47.01 | +17.00% | 1 | Jan 23, 2024 | |
| GSK GSK | Initiates: Equal-Weight | $44 | $33.69 | +30.60% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $64.64 | +31.50% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $105.96 | +13.25% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $96.83
Upside: +17.73%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $47.01
Upside: +17.00%
GSK
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $33.69
Upside: +30.60%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $64.64
Upside: +31.50%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $105.96
Upside: +13.25%